pyrroles has been researched along with Blood Diseases in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Csőszi, T; Dómine Gómez, M; Horton, JK; Jaal, J; Kudaba, I; Malik, RK; Nikolov, K; Radosavljevic, D; Subramanian, J; Xiao, J | 1 |
| Grammatico, S; Petrucci, MT; Scalzulli, E; Vozella, F | 1 |
| Funakoshi, T; Galsky, MD; Latif, A | 1 |
| Beijnen, JH; Cirkel, GA; de Jonge, MJ; Gadellaa-van Hooijdonk, CG; Haanen, JB; Huitema, AD; Kloth, JS; Lankheet, NA; Lolkema, MP; Mathijssen, RH; Schellens, JH; Sleijfer, S; Steeghs, N; Voest, EE | 1 |
| Bryniarski, P; Dumnicka, P; Giza, A; Herman, R; Krzemieniecki, K; Kucharz, J; Kusnierz-Cabala, B; Kuzniewski, M; Zygulska, AL | 1 |
| Bourlon, MT; Breaker, K; Clemons, JE; Flaig, TW; Gao, D; Lam, ET; Trigero, S | 1 |
| Schmidinger, M; Zielinski, CC | 1 |
| Porta, C; Szczylik, C | 1 |
| Crouthamel, MC; Gontarek, RR; King, AG; Kumar, R; Levin, RA; Rominger, DH; Tummino, PJ | 1 |
| Escudier, B; Gore, M; Mickisch, G; Nuijten, M; Procopio, G; Walzer, S | 1 |
| Blumenschein, GR; Chao, RC; Cohen, RB; Heath, EI; Kim, ST; Loconte, NK; Lorusso, PM; Ruiz-Garcia, A; Wilding, G | 1 |
| Desar, IM; Fiedler, W; Grünwald, V; Haanen, J; Mouritzen, U; Olsen, MW; van Herpen, CM | 1 |
| FELDMAN, F; LICHTMAN, HC | 1 |
| Adams, BJ; Baum, CM; Bello, CL; Burstein, HJ; Cobleigh, MA; DePrimo, SE; Eisenberg, PD; Elias, AD; Lehman, M; Miller, KD; Rugo, HS; Wolff, AC | 1 |
| Bell, MR; Bradford, JC; Gelotte, KO; Hlavac, AG; McGarry, RH; Oesterlin, R; Rozitis, J | 1 |
| Winchell, HS | 1 |
| Galambos, JT; Olansky, S; Vogler, WR | 1 |
5 review(s) available for pyrroles and Blood Diseases
| Article | Year |
|---|---|
Proteasome inhibitors for the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Bortezomib; Glycine; Hematologic Diseases; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles | 2018 |
Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Hematologic Diseases; Humans; Incidence; Indoles; Neoplasms; Neutropenia; Publication Bias; Pyrroles; Risk; Sunitinib; Thrombocytopenia | 2013 |
Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Approval; Drug Design; Europe; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Interferons; Kidney Neoplasms; Palliative Care; Patient Selection; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; United States | 2009 |
Tolerability of first-line therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation Disorders; Carcinoma, Renal Cell; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Disease-Free Survival; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypothyroidism; Indoles; Interferons; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Proteins; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sunitinib; Wound Healing | 2009 |
Quantitation of red cell and heme production and destruction using radioisotope kinetics.
Topics: Animals; Autoradiography; Blood Volume Determination; Carbon Isotopes; Carbon Monoxide; Cell Survival; Chromium Isotopes; Erythrocyte Count; Erythrocytes; Esterases; Feces; Guinea Pigs; Haplorhini; Hematologic Diseases; Heme; Humans; Iron; Iron Isotopes; Kinetics; Mathematics; Metabolic Clearance Rate; Phosphorus Isotopes; Pyrroles; Radioisotopes; Tritium | 1968 |
5 trial(s) available for pyrroles and Blood Diseases
| Article | Year |
|---|---|
Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
Topics: Aged; Cytoprotection; Double-Blind Method; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Myeloid Cells; Prognosis; Prospective Studies; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma | 2021 |
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Male; Middle Aged; Neoplasms; Nervous System Diseases; Pilot Projects; Protein Kinase Inhibitors; Pyrroles; Salvage Therapy; Sunitinib | 2014 |
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Endpoint Determination; Female; Half-Life; Hematologic Diseases; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Indoles; Interleukins; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Recombinant Proteins; Sunitinib; Treatment Failure | 2011 |
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Survival Rate; Taxoids | 2008 |
7 other study(ies) available for pyrroles and Blood Diseases
| Article | Year |
|---|---|
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Erythrocyte Indices; Erythrocytes; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2016 |
Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Erythrocyte Indices; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Hematologic Diseases; Hematopoietic Stem Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Myelopoiesis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Substrate Specificity; Sulfonamides; Sunitinib | 2009 |
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; France; Gastrointestinal Diseases; Germany; Health Care Costs; Hematologic Diseases; Hospital Costs; Hospitalization; Humans; Hypertension; Indoles; Interferon alpha-2; Interferon-alpha; Italy; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Recombinant Proteins; Sunitinib; United Kingdom; Venous Thrombosis | 2010 |
In vitro pyrrole and porphyrin synthesis in lead poisoning and iron deficiency.
Topics: Amino Acids; Aminohydrolases; Anemia; Anemia, Hypochromic; Erythrocytes; Hematologic Diseases; In Vitro Techniques; Iron; Lead Poisoning; Porphyrins; Pyrroles | 1963 |
Experimental antiulcer drugs.4. 1,3-Disubstituted 2,4,5,6-tetrahydro-4,6,6 -trimethyl-2-phenylcyclopenta[c]pyrrole-4-carboxamides.
Topics: Animals; Anti-Ulcer Agents; Cyclopentanes; Dogs; Gastric Juice; Haplorhini; Hematologic Diseases; Mice; Pyrroles; Rats; Structure-Activity Relationship | 1980 |
Biochemical effects of chloroquine therapy in porphyria cutanea tarda.
Topics: Ascites; Body Temperature; Chemical and Drug Induced Liver Injury; Chloroquine; Chromatography; Feces; Female; Hematologic Diseases; Humans; Iron; Levulinic Acids; Liver Function Tests; Male; Middle Aged; Porphyrias; Porphyrins; Propionates; Pyrroles; Time Factors | 1970 |